Evidence Table 15

Quality assessments of randomized controlled trials of beta blockers for arrhythmia

Author
Year
Country
Random assignmentAllocation concealedGroups similar at baselineSimilarity to target populationNumber recruitedExclusion criteria for recruitmentEligibility criteria specifiedOutcome assessors blindedCare provider blindedPatient unaware of treatmentIntention-to- treat (ITT) analysisMaintenance of comparable groupsReporting of attrition, crossovers, adherence, and contaminationDifferential loss to follow-up or overall high loss to follow-upScore (good/fair/poor)FundingControl group standard of careLength of follow-up
Head-to- head trials
Katritsis
2003
NRNRYesSelected for patients naïve to study drugs102Terminal illness, age > 80 years, left ventricular ejection fraction <30, concomitant treatment with class I or III antiarrhythmic drugs, amiodarone use within 3 months before randomization, previous treatment with bisoprolol or carvedilol, and contraindications to beta blockade, such as conduction disturbances, asthma, or severe chronic obstructive pulmonary artery diseaseYesYesNRNRNoNRYes
No
No
No
No
No
FairNRYes12 months
Placebo- controlled trials
Metoprolol vs placebo
Kuhlkamp
2000
Adequate, computer generatedNRYesNo - selection for healthier population - mean age of sample = 60 years; mean age atrial fibrillation patients = 75 years403• Use of Class 1 or 3 antiarrhythmic drug, beta- blockers or calcium channel blockers; chronic treatment with amiodarone within 6 months.
• Contraindications to beta-adrenergic blocking agents.
• Untreated thyroid dysfunction
• Paroxysmal atrial fibrillation or history of it
• Cardiac surgery in the previous two months
YesNRYesYesNoYesAttrition=6.8%; others NRNoFairAstraZeneca, SwedenYes6 months
Khand
2003
UK
NRNRYesMean age=68.5
61.7% male
Ethnicity NR
47Heart rate at rest < 60 beats/min, systolic blood pressure < 90 mm Hg, sick sinus syndrome or complete heart block, current treatment with a beta-blocker or HR-lowering calcium channel antagonist or > 200 mg amiodarone, recent major cardiovascular event or procedures, asthma or reversible obstructive airways disease, serum creatinine > 250 μmol/l or significant hepatic disease, uncorrected significant valvular heart disease, or any life-threatening noncardiac diseaseYesYesYesYesYesNRYes
No
No
No
No
No
FairRoche
Pharmaceuticals
YesPhase I=4 months;
Phase II=6 months

From: Beta Adrenergic Blockers: Evidence Tables

Cover of Drug Class Review: Agents for Overactive Bladder
Drug Class Review: Agents for Overactive Bladder: Final Report Update 4 [Internet].
McDonagh MS, Selover D, Santa J, et al.
Portland (OR): Oregon Health & Science University; 2009 Mar.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.